Physician Quick Search
By Name:
By Specialty:
314-TOP-DOCS
When you need to get the name of one of the nation’s top doctors as close to home as St. Louis, just call 314-TOP-DOCS (314-867-3627) or toll free 1-866-867-3627. This is the physician referral and health information line from Barnes-Jewish Hospital.
Your Healthy Update

Like us on Facebook
Text Size: S M L
Search

Internal Medicine / Renal Diseases

Daniel W. Coyne, MD

Current Position
Professor, Medicine
Division of Renal Diseases
Director, Hemodialysis, Chromalloy American Kidney Center
Director, Outpatient Renal Clinics


Specialty Areas
Nephrology
Dialysis Management
Kidney Disease

Patients Seen At
Center for Advanced Medicine
Medicine Multispecialty Center
4921 Parkview Place, C, 5
St. Louis, MO  63110
314-362-7603
Fax:   314-747-3743
View Floor Map  View Campus Map   View Driving Directions

Chromalloy American Kidney Center
4950 Children’s Place
St. Louis, MO  63110
314-362-7209
Fax:   314-362-7232
View Driving Directions

Davita St. Louis Dialysis
2610 Clark Avenue
St. Louis, MO  6103
314-534-0909
Fax:   314-534-0661
View Driving Directions

Mailing Address
Washington University School of Medicine, Division of Renal Diseases
660 South Euclid Avenue, Campus Box 8126
St. Louis, MO  63110

Areas of Clinical Interest
Chronic kidney disease, hemodialysis, high blood pressure, hypertension, proteinuria, hematuria, anemia

Board Certification
Internal Medicine -- Certified
Nephrology -- Certified

Medical Education
B.A.: Chemistry, St. Louis University, St. Louis, Missouri, 1979
Medical Degree: Case Western Reserve, Cleveland, Ohio, 1983
Residency: Internal Medicine, Emory University Medicine Program, Atlanta, Georgia, 1986
Fellowship: Nephrology, Washington University School of Medicine, St. Louis, Missouri, 1989
Hospital Affiliations
Barnes-Jewish Hospital

Honor and Awards
Listed in Best Doctors in America, 2003-2013 (Best Doctors, Inc.)

Disclosure of Financial Interests with Industry
Washington University and its physicians are committed to ensuring integrity and objectivity in medical decision-making. Some of our physicians work collaboratively with pharmaceutical or medical device companies to develop innovative ideas and products that can improve health care delivery and clinical outcomes for patients. In some instances, our faculty physicians are paid by these commercial companies to provide advice on product design or to speak about the use of medications, devices, equipment or procedures. These payments may include: a) compensation for consulting and speaking engagements, b) equity, and/or c) royalties for products invented by our faculty. Any payments to Washington University physicians must be based on tangible services and may not exceed fair market value for their work. In addition to disclosure on this web site, physicians earning more than $10,000 per year must disclose their corporate financial relationship in writing to patients when prescribing or using that company's products.

Dr. Daniel W. Coyne reported the following earned financial interests during calendar year 2013. Move your mouse over a header for more info.
Company
Royalties
Royalties: When a faculty member invents or conceives a new or improved process or product, the company that manufactures the product will make royalty payments to the faculty member. Royalty payments usually are a small percentage of the company’s revenue related to that product.
Consulting &
Advisory Boards
Consulting and Advisory Boards: Faculty may be paid to provide expertise to a company by being their consultant, or by serving on an advisory board.
Speaker Fees
Speaker Fees: Companies may pay faculty to speak to professional audiences about their products.
Abbott  $1,000-$10,000 $25,001-$50,000 
To learn more about Washington University's policies on collaborations with industry, click here.

Editorial Responsibilities

Editorial Board Member
Journal of the American Society of Nephrology

Ad Hoc Reviewer
American Journal of Kidney Diseases

Selected or Recent Journal Articles
Coyne DW, Andress DL, Amdahl MJ, Ritz E, de Zeeuw D. Effects of paricalcitol on calcium and phosphate metabolism and markers of bone health in patients with diabetic nephropathy: results of the VITAL study. Nephrol Dial Transplant. 2013 Sep;28(9):2260-8.

Coyne DW. Anemia management in dialysis: Why the FDA and CMS have it right (and how KDIGO got it wrong). Nephrol News Issues. 2013 Feb;27(2):16, 18, 20. No abstract available.

Brown AJ, Coyne DW. Bioavailable vitamin D in chronic kidney disease. Kidney Int. 2012 Jul.

Coyne DW. The health-related quality of life was not improved by targeting higher hemoglobin in the Normal Hematocrit Trial. Kidney Int. 2012 Jul.

Wang X, Belani S, Coyne DW, Fabbrini E, Reeds DN, Patterson BW, Mittendorfer B, Klein S. Very Low Density Lipoprotein Metabolism in Patients with Chronic Kidney Disease. Cardiorenal Med. 2012 Feb.

Coyne DW. Hepcidin: clinical utility as a diagnostic tool and therapeutic target. Kidney Int. 2011 Aug.

Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, Wanner C, Krane V, Cass A, Craig J, Neal B, Jiang L, Hooi LS, Levin A, Agodoa L, Gaziano M, Kasiske B, Walker R, Massy ZA, Feldt-Rasmussen B, Krairittichai U, Ophascharoensuk V, Fellström B, Holdaas H, Tesar V, Wiecek A, Grobbee D, de Zeeuw D, Grönhagen-Riska C, Dasgupta T, Lewis D, Herrington W, Mafham M, Majoni W, Wallendszus K, Grimm R, Pedersen T, Tobert J, Armitage J, Baxter A, Bray C, Chen Y, Chen Z, Hill M, Knott C, Parish S, Simpson D, Sleight P, Young A, Collins R; SHARP Investigators. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet. 2011 Jun 25.

Camins BC, Richmond AM, Dyer KL, Zimmerman HN, Coyne DW, Rothstein M, Fraser VJ. A crossover intervention trial evaluating the efficacy of a chlorhexidine-impregnated sponge in reducing catheter-related bloodstream infections among patients undergoing hemodialysis. Infect Control Hosp Epidemiol. 2010 Nov.

Ford BA, Eby CS, Scott MG, Coyne DW. Intra-individual variability in serum hepcidin precludes its use as a marker of iron status in hemodialysis patients. Kidney Int. 2010 Oct.

Coyne DW, Auerbach M. Anemia management in chronic kidney disease: intravenous iron steps forward.  Am J Hematol. 2010 May.

Coyne DW. It's time to compare anemia management strategies in hemodialysis. Clin J Am Soc Nephrol. 2010 Apr.

Coyne DW. Ferumoxytol for treatment of iron deficiency anemia in patients with chronic kidney disease.Expert Opin Pharmacother. 2009 Oct.

Young DO, Cheng SC, Delmez JA, Coyne DW. The effect of oral niacinamide on plasma phosphorus levels in peritoneal dialysis patients.Perit Dial Int. 2009 Sep-Oct.

Coyne DW, Brennan DC. Seeking safe and efficacious anemia management.. Semin Dial. 2009 Sep-Oct.

Gincherman Y, Moloney K, McKee C, Coyne DW.Assessment of adherence to cinacalcet by prescription refill rates in hemodialysis patients. Hemodial Int. 2009 Aug 28.

For more articles and abstracts, take this off-site link to the National Library of Medicine Pub Med page for Dr. Daniel Coyne.


Washington University Physicians are the medical staff of  Barnes-Jewish Hospital and Children's Hospital - St. Louis Employment   About Us   Top Stories   For Your Protection      Site Map
Copyright 2014 Washington University School of Medicine
Copyright 2014 Washington University School of Medicine